Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Schizophrenia, Bipolar I Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Little Rock, Arkansas • Garden Grove, California • Berlin, New Jersey + 1 more

Conditions: Major Depressive Disorder
Interventions: Antidepressant + Placebo, Antidepressant + Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Beverly Hills, California • Burbank, California • National City, California + 25 more

Conditions: Bipolar I Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Chula Vista, California + 10 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 4 Years to 9 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia, Cocaine Dependence
Interventions: Aripiprazole, Perphenazine; Drug
Lead sponsor: Paul Saenger; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bacterial Conjunctivitis
Interventions: VIGAMOX; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Year to 13 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Non-Hodgkin's Lymphoma, Cancer
Interventions: Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Healthy
Interventions: Saline, PF-02545920, Ketamine, Placebo; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Healthy Subjects, Cardiac Repolarization
Interventions: Placebo, ASP1941, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Pilocarpine, Ofloxacin, Prednisolone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Schizophrenia
Interventions: Olanzapine, Aripiprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 24
States / cities: Little Rock, Arkansas • Garden Grove, California • National City, California + 21 more

Conditions: Autoimmune Diseases
Interventions: CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin; Drug
Lead sponsor: Connect Biopharma Australia Pty Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
Interventions: Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG, Ciprofloxacin 500 mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetic Foot Ulcer
Interventions: gentamicin-collagen sponge, Levofloxacin; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pasadena, Maryland

Conditions: Contraception
Interventions: Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteomyelitis of Jaw
Interventions: Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Complicated Urinary Tract Infection, Pyelonephritis
Interventions: CXA-201, Levofloxacin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: San Diego, California • Wheat Ridge, Colorado • Hialeah, Florida + 2 more

Conditions: Healthy
Interventions: sisunatovir, placebo, moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar I
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more

Conditions: Osteomyelitis
Interventions: Intravenous Antibacterial Agent, Oral Antibacterial Agent; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Cystic Fibrosis
Interventions: Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

Pilocarpine After Combined Cataract/Trabectome Surgery

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode